Tradestie Institutional Equity Comparison Engine

GBIO vs AVDL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-02-11 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AVDL Overall Edge

AVDL Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GBIO counters with relative strength in Valuation. Fundamentally, GBIO trades at 7.9x Forward P/E with -2020.0% operating margin (-78.9% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, GBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GBIO
GBIO 7.9x vs AVDL 28.8x Fwd P/E
Growth & Margin Winner AVDL
Op Margin -2020.0% vs 2.5% ยท YoY -78.9% vs +54.9%
Momentum & Technical Winner AVDL
1Y -35.8% vs +138.1% ยท 52W Pos 62% vs 89%
Options & Structure Winner AVDL
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (<1st %ile IV)
GBIO NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
$5.34
-6.97% 1D
Market Cap $38.7M
1M Return -2.38%
1Y Return -35.83%
Forward P/E 7.9x
Unified AI Score
58.8 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 53.9
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
1M Return +0.65%
1Y Return +138.06%
Forward P/E 28.8x
Unified AI Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GBIO -35.83% AVDL +138.06% Spread: +162.32 pp (AVDL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GBIO TTM Op. Margin: -2020.0% AVDL TTM Op. Margin: 2.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GBIO vs AVDL. Trailing 12-month operating profitability (GBIO -2020.0% vs AVDL 2.5%) and valuation multiples (GBIO 7.9x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GBIO (2) vs AVDL (7)
Institutional Metric GBIO AVDL Criterion Row Winner
Market Capitalization Scale $38.7M $2.1B Larger Scale AVDL
Trailing P/E Ratio Valuation 7.9x 16.8x Lower Multiple GBIO
Forward P/E Ratio Valuation 7.9x 28.8x Lower Multiple GBIO
Revenue Growth (YoY) Growth -78.9% +54.9% Higher Growth AVDL
Operating Margin (TTM) Profitability -2020.0% 2.5% Higher Margin AVDL
Net Profit Margin Profitability 0.0% -0.1% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -80.8% -0.3% Higher ROE AVDL
52-Week Range Position Momentum 62% ($0โ€“$8) 89% ($6โ€“$24) Stronger Trend AVDL
Beta / 30D Volatility Risk Regime 0.80ฮฒ ยท 26% Vol 0.14ฮฒ ยท 2% Vol Lower Realized Risk AVDL
Unified Institutional Score Composite Signal 58.8 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AVDL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GBIO vs AVDL Buy Guide
GBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live AVDL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GBIO nor AVDL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.